

Nu Skin Enterprises Reports Strong First-Quarter Results And Increases Annual Guidance

April 26, 2018

PROVO, Utah, April 26, 2018 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS) today announced first-quarter financial results and increased its annual guidance.



Executive Summary

Q1 2018 vs. Prior-Year Quarter

Revenue:	\$616.2 million, +24% • +7% fx impact
Earnings Per Share	\$0.64, which includes a \$0.12 negative impact associated with the settlement of a convertible note and a \$0.03 charge
(EPS):	from purchase accounting, compared to \$0.51
Sales Leaders:	63,500, +16%
Customers:	1,086,000, +11%

"We delivered strong first-quarter results highlighted by 24 percent growth in revenue, which included a 7 percent foreign currency benefit," said Ritch Wood, chief executive officer. "Our revenue growth was driven by an 11 percent increase in customers and a 16 percent improvement in the number of sales leaders. We are encouraged by the early execution of our growth strategy centered on engaging platforms, enabling products and empowering programs."

Q1 2018 Year-Over-Year Operating Results

Revenue:	\$616.2 million compared to \$499.1 million
Gross Margin:	76.3% compared to 77.7%
Gross Margin.	Gross margin of core Nu Skin business was 77.9%
Selling Expenses:	41.8% of revenue compared to 41.9%
G&A Expenses:	24.9% of revenue compared to 26.6%
Operating Margin:	9.6% compared to 9.3%
Other Income /	\$1.2 million income compared to (\$4.6) million expense
(Expense):	\$1.2 million income compared to (\$4.6) million expense
Income Tax Rate:	41.0% compared to 34.1%
EPS:	\$0.64, which includes a \$0.12 impact associated with the settlement of a convertible note and a \$0.03 charge from
EP3:	purchase accounting, compared to \$0.51

Stockholder Value

Dividend Payments:	\$19.8 million
Stock Repurchases:	\$17.4 million; \$110.6 million remaining in authorization

Q2 and Full-Year 2018 Outlook

Q2 2018 Revenue:	\$630 to \$650 million, 15% to 18% growth
	Approximately +5% fx impact
Q2 2018 EPS:	\$0.86 to \$0.91 which includes an estimated \$0.05 purchase accounting charge
2018 Revenue:	\$2.51 billion to \$2.56 billion, 10% to 12% growth
	Approximately +3% fx impact
2018 EPS	\$3.45 to \$3.65 which includes the first quarter \$0.12 convertible note impact and an estimated \$0.16 purchase accounting
	charge for the year

[&]quot;Based on the strength of first-quarter results and our initiatives for the remainder of the year, we are increasing our annual revenue guidance by \$70 million," said Wood. "We remain focused on building momentum and executing our customer growth strategy by increasing social sharing capabilities with additional training and tools, driving innovation with ageLOC LumiSpa and other new products, and continuing the roll out of Velocity, our enhanced sales compensation program."

"We generated 24 percent year-over-year revenue growth and strong earnings performance in the quarter," said Mark Lawrence, chief financial officer. "As previously disclosed, we incurred a charge associated with the early conversion of our convertible note, which was not included in our original guidance and negatively impacted first-quarter earnings by \$0.12 per share. In addition, due to purchase accounting, we incurred a \$0.03 charge related to the amortization of intangibles from our recent acquisitions.

"For the year, we are increasing our annual revenue guidance to \$2.51 billion to \$2.56 billion with earnings per share of \$3.45 to \$3.65. This earnings guidance reflects the \$0.12 negative impact related to the convertible note and approximately \$0.16 of estimated amortization of intangibles from the acquisitions which were not included in our previous guidance. The most significant impact of the amortization will be in 2018. We are projecting second-quarter revenue of \$630 to \$650 million and earnings per share of \$0.86 to \$0.91," concluded Lawrence.

Conference Call

The Nu Skin management team will host a conference call with the investment community on April 26, 2018, at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at <u>ir.nuskin.com</u>. A replay of the webcast will be available at the same URL through May 10, 2018.

About Nu Skin Enterprises, Inc.

Founded more than 30 years ago, Nu Skin Enterprises, Inc. develops and distributes innovative consumer products, offering a comprehensive line of premium-quality beauty and wellness solutions. The company builds upon its scientific expertise in both skin care and nutrition to continually develop innovative product brands that include the Nu Skin[®] personal care brand, the Pharmanex[®] nutrition brand, and most recently, the ageLOC[®] anti-aging brand. The ageLOC brand has generated a loyal following for such products as the ageLOC LumiSpa skin cleansing and treatment device, ageLOC Youth nutritional supplement, the ageLOC Me[®] customized skin care system, as well as the ageLOC TR90[®] weight management and body shaping system. Nu Skin sells its products through a global network of sales leaders in Asia, the Americas, Europe, Africa and the Pacific. As a long-standing member of direct selling associations globally, Nu Skin is committed to the industry's consumer guidelines that protect and support those who sell and purchase its products through the direct selling channel. Nu Skin is also traded on the New York Stock Exchange under the symbol "NUS." More information is available at nuskin.com.

Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding the company's performance, growth, strategies and initiatives; projections regarding revenue, earnings per share, foreign currency fluctuations, tax rates and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "project," "anticipate," "estimate," "intend," "plan," "continue," "targets," "likely," "will," "would," "could," "may," "might," the negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

- adverse publicity related to the company's business, products, industry or any legal actions or complaints by the company's sales force or others;
- risk that direct selling laws and regulations in any of our markets, including the United States and Mainland China, may be
 modified, interpreted or enforced in a manner that results in negative changes to our business model or negatively impacts
 our revenue, sales force or business, including through the interruption of sales activities, loss of licenses, imposition of
 fines, or any other adverse actions or events;
- any failure of current or planned initiatives or products to generate interest among the company's sales force and customers and generate sponsoring and selling activities on a sustained basis;
- risk of foreign currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;
- uncertainties regarding the future financial performance of the company's recent acquisitions;
- risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support our planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;
- regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit the company's ability to import or continue selling a product in a market if it is determined to be a medical device or if it is unable to register the product in a timely manner under applicable regulatory requirements;
- unpredictable economic conditions and events globally;
- uncertainties related to interpretation of, and forthcoming regulations under, the recently enacted U.S. tax reform legislation; the company's future tax-planning initiatives; any prospective or retrospective increases in duties on the company's products imported into the company's markets outside of the United States; and any adverse results of tax audits or unfavorable changes to tax laws in the company's various markets; and
- continued competitive pressures in the company's markets.

The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's beliefs as of the date that such information was first provided and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

Non-GAAP Financial Measures: Constant-currency revenue growth is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company's performance. It is calculated by translating the current period's revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount to the prior-year period's revenue.

The Company's revenue results by segment for the three-month periods ended March 31 are presented in the following table (in thousands).

		2018			2017	% Change	Constant Currency % Change
Mainland China	\$	197.531	\$:	150.004	32%	22%
Americas/Pacific	Ψ	92,289	Ψ	,	71,425	29%	32%
South Korea		88,930			82,471	8%	1%
Southeast Asia		70,860			63,025	12%	7%
Japan		63,224			61,156	3%	(2%)
EMEA		44,981			34,064	32%	15%
Hong Kong/Taiwan		40,992			35,948	14%	11%
Other		17,412	_		1,006	1,631%	1,631%
Total	\$	616,219	\$	3	499,099	24%	17%

The company's Customers and Sales Leaders statistics by segment for the three-month periods ended March 31are presented in the following table.

	2018	8	2017	7	% Increase (Decrease)		
	Customers	Sales Leaders	Customers	Sales Leaders	Customers	Sales Leaders	
Mainland China Americas/Pacific South Korea Southeast Asia Japan EMEA Hong Kong/Taiwan	200,000 246,000 179,000 118,000 129,000 142,000 72,000	27,000 8,200 7,300 6,600 6,200 4,300 3,900	176,000 191,000 189,000 98,000 132,000 124,000 70,000	19,100 6,900 8,000 6,200 6,400 4,100 3,900	14% 29% (5%) 20% (2%) 15% 3%	41% 19% (9%) 6% (3%) 5%	
Total	1,086,000	63,500	980,000	54,600	11%	16%	

[&]quot;Customers" are persons who purchased products directly from the company during the previous three months.

NU SKIN ENTERPRISES, INC. Consolidated Statements of Income (Unaudited) For the First Quarters Ended March 31, 2018 and 2017

(in thousands, except per share amounts)

	2018		2017	
Revenue	\$	616,219	\$	499,099
Cost of sales		146,281		111,266
Gross profit		469,938		387,833
Operating expenses: Selling expenses General and administrative expenses		257,702 153,246		209,008 132,563
Total operating expenses Operating income		410,948 58,990		341,571 46,262
Other income (expense), net Income before provision for income taxes Provision for income taxes		1,207 60,197 24,658		(4,567) 41,695 14,206
Net income	\$	35,539	\$	27,489

[&]quot;Sales Leaders" are independent distributors, and sales employees and independent marketers in China, who achieve certain qualification requirements.

Net income per share:

Basic	\$	0.66	\$ 0.52
Diluted	\$	0.64	\$ 0.51
Weighted average common shares outstanding	1-		
Basic Basic		53.997	52.678
Dasic		53,997	52,676
Diluted		55,959	54,057

NU SKIN ENTERPRISES, INC. Consolidated Balance Sheets (Unaudited)

(in thousands)

		March 31, 2018		December 31, 2017	
ASSETS					
Current assets:					
Cash and cash equivalents	\$	421,484	\$	426,399	
Current investments		8,615		11,847	
Accounts receivable		54,014		33,196	
Inventories, net		282,983		253,454	
Prepaid expenses and other		66,705		52,893	
		833,801		777,789	
Property and equipment, net		508,476		464,587	
Goodwill		187,423		114,954	
Other intangible assets, net		100,601		67,647	
Other assets		144,368		164,895	
Total assets	\$	1,774,669	\$	1,589,872	
LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities:					
Accounts payable	\$	62,253	\$	50,341	
Accrued expenses		309,536		319,189	
Current portion of long-term debt		362,659		77,840	
·		734,448		447,370	
Long-term debt		107,275		310,790	
Other liabilities		133,818		127,116	
Total liabilities		975,541		885,276	
Stockholders' equity:					
Class A common stock		91		91	
Additional paid-in capital		523,233		466,349	
Treasury stock, at cost		(1,280,586)		(1,304,694)	
Accumulated other comprehensive loss		(55,474)		(66,318)	
Retained earnings		1,611,864		1,609,168	
<u> </u>		799,128		704,596	
Total liabilities and stockholders' equity	\$	1,774,669	\$	1,589,872	

Nu Skin Social Media Channels

• fb.com/nuskin • twitter.com/nuskin • instagram.com/nuskin

Usew original content with multimedia: http://www.prnewswire.com/news-releases/nu-skin-enterprises-reports-strong-first-quarter-results-and-increases-annual-guidance-300637582.html

SOURCE Nu Skin Enterprises, Inc.

Media: media@nuskin.com, (801) 345-6397, or Investors: investorrelations@nuskin.com, (801) 345-3577